TherapeuticsMD Gross Profit

The latest gross profit for TXMD is $2.2M as of June 2026. That compares with $1.4M in the prior-year period — up 51.9% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside TherapeuticsMD's historical trend and sector peers before judging valuation or financial health.

Over the past year, TXMD's gross profit moved from $1.4M to $2.2M — a 51.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TherapeuticsMD's operating scale or balance-sheet position.

Against Healthcare companies, TXMD currently prints $2.2M for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at TherapeuticsMD's growth, margins, and balance sheet.

A gross profit figure of $2.2M for TXMD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting TXMD's gross profit ($2.2M), review year-over-year change from $1.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.